Exact Mass: 481.2577
Exact Mass Matches: 481.2577
Found 192 metabolites which its exact mass value is equals to given mass value 481.2577
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-Acetyl-leukotriene E4
N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886) [HMDB] N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886).
7,14-Dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine
7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is an acylcarnitine. More specifically, it is an 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-acetyl Leukotriene E4
Ala Tyr Thr Lys
Ala Thr Tyr Lys
Phe Thr Ser Lys
Ala Lys Thr Tyr
Ala Lys Tyr Thr
Ala Thr Lys Tyr
Ala Tyr Lys Thr
Phe Lys Ser Thr
Phe Lys Thr Ser
Phe Ser Lys Thr
Phe Ser Thr Lys
Phe Thr Lys Ser
His Ile Asn Val
His Ile Val Asn
His Lys Pro Thr
His Lys Thr Pro
His Leu Asn Val
His Leu Val Asn
His Asn Ile Val
His Asn Leu Val
His Asn Val Ile
His Asn Val Leu
His Pro Lys Thr
His Pro Thr Lys
His Gln Val Val
His Thr Lys Pro
His Thr Pro Lys
His Val Ile Asn
His Val Leu Asn
His Val Asn Ile
His Val Asn Leu
His Val Gln Val
His Val Val Gln
Ile His Asn Val
Ile His Val Asn
Ile Asn His Val
Ile Asn Val His
Ile Val His Asn
Ile Val Asn His
Lys Ala Thr Tyr
Lys Ala Tyr Thr
Lys Phe Ser Thr
Lys Phe Thr Ser
Lys His Pro Thr
Lys His Thr Pro
Lys Pro His Thr
Lys Pro Thr His
Lys Ser Phe Thr
Lys Ser Thr Phe
Lys Thr Ala Tyr
Lys Thr Phe Ser
Lys Thr His Pro
Lys Thr Pro His
Lys Thr Ser Phe
Lys Thr Tyr Ala
Lys Tyr Ala Thr
Lys Tyr Thr Ala
Leu His Asn Val
Leu His Val Asn
Leu Asn His Val
Leu Asn Val His
Leu Val His Asn
Leu Val Asn His
Asn His Ile Val
Asn His Leu Val
Asn His Val Ile
Asn His Val Leu
Asn Ile His Val
Asn Ile Val His
Asn Leu His Val
Asn Leu Val His
Asn Val His Ile
Asn Val His Leu
Asn Val Ile His
Asn Val Leu His
Pro His Lys Thr
Pro His Thr Lys
Pro Lys His Thr
Pro Lys Thr His
Pro Thr His Lys
Pro Thr Lys His
Gln His Val Val
Gln Val His Val
Gln Val Val His
Ser Phe Lys Thr
Ser Phe Thr Lys
Ser Lys Phe Thr
Ser Lys Thr Phe
Ser Thr Phe Lys
Ser Thr Lys Phe
Thr Ala Lys Tyr
Thr Ala Tyr Lys
Thr Phe Lys Ser
Thr Phe Ser Lys
Thr His Lys Pro
Thr His Pro Lys
Thr Lys Ala Tyr
Thr Lys Phe Ser
Thr Lys His Pro
Thr Lys Pro His
Thr Lys Ser Phe
Thr Lys Tyr Ala
Thr Pro His Lys
Thr Pro Lys His
Thr Ser Phe Lys
Thr Ser Lys Phe
Thr Tyr Ala Lys
Thr Tyr Lys Ala
Val His Ile Asn
Val His Leu Asn
Val His Asn Ile
Val His Asn Leu
Val His Gln Val
Val His Val Gln
Val Ile His Asn
Val Ile Asn His
Val Leu His Asn
Val Leu Asn His
Val Asn His Ile
Val Asn His Leu
Val Asn Ile His
Val Asn Leu His
Val Gln His Val
Val Gln Val His
Val Val His Gln
Val Val Gln His
Tyr Ala Lys Thr
Tyr Ala Thr Lys
Tyr Lys Ala Thr
Tyr Lys Thr Ala
Tyr Thr Ala Lys
Tyr Thr Lys Ala
N-acetyl-Leukotriene E4
2-Methyl-4-dibenzylaminobenzaldehyde-1,1-diphenylhydrazone
4-(2-(6-(Dibutylamino)-2-naphthalenyl)ethenyl)-1-(3-sulfopropyl)pyridinium hydroxide inner salt, >=95\\% (HPLC), solid
7,14-Dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine
(8R,9R,10S)-9-[4-(1-cyclohexenyl)phenyl]-N-(2,5-difluorophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4S,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propanoyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4S,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone
N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propanoyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4R,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propanoyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4S,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone
N-[(4R,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4S,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
(8R,9S,10R)-9-[4-(1-cyclohexenyl)phenyl]-N-(2,5-difluorophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10R)-9-[4-(1-cyclohexenyl)phenyl]-N-(2,5-difluorophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
BML1-E10
A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an N-acetyl-L-cystein-S-yl group at position 6 (6R); it is a major bilary metabolite of cysteinyl leukotrienes.
(2s,3ar,9as,10ar)-9'-methoxy-1,1,5',5'-tetramethyl-3a-nitro-4,6,7,8,9,9a,10,10a-octahydro-3h-4'-azaspiro[cyclopenta[b]quinolizine-2,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),8'(12'),9'-triene-3',7'-dione
n-{2-[5-(acetyloxy)-6-oxocyclohex-1-en-1-yl]-3-chloroprop-2-en-1-yl}-7-methoxytetradec-4-enimidic acid
14-o-acetyltakaosamine
{"Ingredient_id": "HBIN001536","Ingredient_name": "14-o-acetyltakaosamine","Alias": "NA","Ingredient_formula": "C25H39NO8","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4C5C6OC(=O)C)OC)O)O)OC)O)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "518","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}